Dose/Regimen
Comments
0.5 mL IM
Administer to asplenic patients and those with
history of recurrent Haemophilus infection.
1 mL IM with revaccination in
6-12 months for Havrix® or 6-18
months for Vaqta®; also available in
combination with hepatitis B vaccine
as Twinrix® administered as 3 or 4
dose
Hepatitis A vaccination is recommended for all
susceptible men who have sex with men, as well
as others with indications for hepatitis A virus
vaccine (eg, injection drug users, persons with
chronic liver disease or who are infected with
hepatitis B and/or C).
Engerix B® 20 μg or Recombivax HB®
10 μg IM given at 0, 1, and 6 months;
also available in combination with
hepatitis A vaccine as Twinrix®
administered as 3 or 4 dose
Administer to patients without evidence of past
or present hepatitis B infection. Vaccinated
patients should be tested for HBsAb response
after the third dose; higher dose (40 μg) booster
or series may be considered for nonresponders.
Gardasil® 0.5mL IM for 3 dose series
given at 0, 2, and 6 months
Safety and immunogenicity studies in those
with HIV infection are on-going.
0.5 mL IM annually
ALL patients, especially important in patients
at high risk for exposure to or morbidity from
influenza.
0.5 mL IM of the 23 polyvalent
polysaccharide vaccine
Administer to patients with CD4 cell count
≥ 200/mm3. Consider booster dose 5 years after
initial immunization.
0.5 mL SC; three doses over 6-12
months for primary immunization
Td 0.5 mL IM
Tdap 0.5-0.75 mL IM as per package
insert
Substitute 1 time dose of Tdap vaccine at
time of next booster, then Td every 10 years.
Precautions with pregnancy. Td may be
administered during 2nd or 3rd trimester or defer
Td during pregnancy and administer Tdap
postpartum
0.5 mL IM as 2 doses administered
3 months apart
Administer to HIV-infected persons with a
CD4 count ≥ 200 cells/mm3 who do not have
evidence of immunity to varicella
9